Age, period and cohort effects on mortality from cervical cancer in Colombia between 1985 and 2014.

Efectos de edad, periodo y cohorte en la mortalidad por cáncer de cuello uterino en Colombia entre 1985 y 2014.

Lina Angélica Buitrago Reyes1,2, Oscar Andrés Gamboa Garay2, Jairo Alonso Hernández2,4
labuitragor@unal.edu.co

1 Facultad de Ciencias. Departamento de Estadística. Universidad Nacional de Colombia, Bogotá, Colombia. 2 Instituto para la Evaluación de la Calidad y Atención (IECAS), Bogotá, Colombia. 3 Instituto Nacional de Cancerología, Bogotá, Colombia, 4 Facultad de Medicina y Ciencias de la Salud. Universidad Militar Nueva Granada, Bogotá, Colombia.

Abstract

Objective:
To analyze the cervix cancer mortality in Colombia, based on age, period and cohort effects.

Methods:
The mortality and population data were taken from the official databases of the National Administrative Department of Statistics, DANE. Five models were adjusted, the significance of the effects was obtained by comparing them through the likelihood ratio test.

Results:
The age-adjusted mortality rate, in deaths was 15.09/100,000 woman, at 1985-1989 period, and 10.21 at 2010-2014 period. The annual percentage average change was -1.45% (95% CI: -1.57% to -1.34%). Age, period and cohort effects were found.

Conclusions:
Demographic factors could explain the behavior of cervical cancer mortality in Colombia, as well as the establishment of public health measures in the last two decades.
Resumen

Objetivo:
Analizar las tendencias de la mortalidad por cáncer de cuello uterino en Colombia, teniendo en cuenta los efectos de edad, periodo y cohorte.

Métodos:
Los datos de mortalidad y de población se tomaron de las bases oficiales del Departamento Administrativo Nacional de Estadísticas, DANE. Se ajustaron cinco modelos, la significancia de los efectos se obtuvo comparándolos a través de la prueba de razón de verosimilitud.

Resultados:
La tasa de mortalidad ajustada por edad, en muertes fue de 15.09/100,000 mujeres, para el periodo 1985-1989 y 10.21 para el periodo 2010-2014. El cambio promedio porcentual anual fue de -1.45% (IC 95%: -1.57% a -1.34%). Se encontraron efectos de edad, periodo y cohorte.

Conclusiones:
Los factores demográficos podrían explicar el comportamiento de la mortalidad por cáncer de cuello uterino en Colombia, al igual que la instauración de medidas de salud pública en las dos últimas décadas.

Remark

1) Why was this study conducted?
This study was conducted because we wanted to describe the changes in cervical cancer mortality over time, separating each of the effects. In such a way that we could be clear about the behavior for each age group, each period or each cohort and thus be able to associate interventions that could explain these trends.

2) What were the most relevant results of the study?
We found that cervical cancer mortality is explained by age, period, and cohort effects. The most relevant changes could be associated with interventions that modified the frequency of risk factors or cofactors, that helped early diagnosis or that increased progression-free survival.

3) What do these results contribute?
The results are an important input for new research questions, for example, to determine the influence of each of the interventions on cervical cancer frequencies. On the other hand, they show that APC models are an important input when analyzing the temporal trends of a health event, particularly for cervical cancer mortality, since they allow a more precise analysis of the possible consequences of specific interventions.
Introduction

By 2020, cervical cancer was the third cause of incidence and the fifth cause of cancer mortality in Colombian women. There were 4,742 new cases and 2,490 deaths were reported, with a crude incidence rate of 18.3 cases per 100,000 women and a mortality rate of 10.1 per 100,000 women. On the other hand, in 1990 it also ranked third in incidence and mortality, with a crude rate of 22.3 per 100,000 women and a mortality rate of 6.2 per 100,000 women. Therefore, despite observing a clear decrease in both incidence and mortality, it continues to be a pathology of great importance that requires improvements in screening programs, prevention strategies, and improved opportunities for access to treatment, as well as the analysis of the behavior of its frequencies is relevant.

In Latin America and the Caribbean, Colombia ranks 19th (out of 30) in incidence with an age-standardized rate of 14.9 per 100,000 women, equal to the rate for the entire region, while in mortality it ranks 22nd with an adjusted rate by age of 7.4 per 100,000 women.

The analysis of the cancer mortality trend has been studied in different regions of the world and has even been analyzed as an indicator of quality of life. Cancer incidence and mortality rates are closely monitored to track the burden of cancer and its evolution in different populations, provide etiological theories and hypotheses of the different types of cancer, show inequalities, and evaluate: the diffusion, implementation, and possible effects of the different kinds of procedures for early detection, diagnosis, and therapeutic innovations.

A standard “toolbox” of graphical and quantitative methods for the analysis of cancer incidence and mortality has been developed. Perhaps the most widely used methods include classic descriptive plots based on the Lexis diagram, age-standardized rates, estimated annual percentage change, and the jointpoint regression method. However, this type of methodology does not allow discriminating the effects of age, period and cohort. The age-period-cohort (APC) model has been developed in the statistical literature as a mathematical counterpoint to purely descriptive approaches, which is based on fundamental generalized linear model theory and allows the epidemiologist to generate and test hypotheses about the trends.

The age-period-cohort (APC) models identify whether the changes in the incidence or mortality of the disease are due to the effects of changes in the age of the population; to factors located at a moment in time and that have an influence on all age groups simultaneously, generally associated with period effects (date of death); or to factors that affect a generation (birth cohort), which show changes of magnitude in the rates of the different age groups in successive periods. Likewise, the APC models are adjusted to determine the effect of each of these factors, separately, on the evolution of an outcome over time.

In Colombia, these types of models have not been adjusted for the analysis of mortality from cervical cancer. This paper aims to determine the temporal effects, through an APC model of cervical cancer mortality in Colombia, during the period 1985-2014, following the methodology proposed by Carstensen.

Materials and Methods

The information on mortality from cervical cancer for the period 1985-2014 was obtained from the official records of death certificates processed by National Department of Statistics (DANE). Information on age, date of death, place of residence and underlying cause of death was used from each record. Information on deaths from cancer in patients older than 20 years was included.

The basic cause of death was coded by DANE according to the International Classification of Diseases (ICD). Until 1997 the ICD-9 was used and later the ICD-10. The ICD codes used were 180.0 and 180.1 for ICD-9 and C53.0, C53.1 for ICD-10. Cases without age and with
residence abroad were eliminated. Population projections for Colombia made by DANE were used to estimate the population at risk. Ages and periods were grouped in five-year groups from 20 years old to reaching the category of 80 years or more.

Truncated age-adjusted rates, starting at age 20, were calculated using the Segi world reference population, for each period.

To model mortality rates as a function of age (a), period (p), and cohort (c), a generalized linear model with Poisson response, canonical link function (natural logarithm), including age, period and cohort as factors. Five models were adjusted: age, age-drift, age-cohort, age-period-cohort and age-period, which were compared through the likelihood ratio test, to establish the significance of each of the effects.

To fit the age-period-cohort model, an age-drift model was first fitted, estimating the average annual percentage change (APPC) in mortality rates during the 30 years of observation (Equation 1).

$$ \log(\lambda_{ap}) = \alpha_a + \delta p + \epsilon $$

Where $\alpha_a$ is the effect of age group $a$, $\epsilon$ is the random error and $\delta$ the slope of the period (drift), which allows calculating the APPC of mortality rates, adjusted for age (Equation 2).

$$ CPPA = (\exp(\delta) - 1) \times 100 $$

For a more detailed description of mortality, an age-period-cohort model was fitted to the rates $\lambda_{ap}$, using the methodology proposed by Carstensen. The estimates were obtained by maximum likelihood, under the restriction that the effects of the period are zero on average and with zero slope, taking ages, periods and cohorts as factors (Equation 3).

$$ \log(\lambda_{ap}) = \mu + \alpha_a + \beta_c + \gamma_p + \epsilon $$

The exponential of the age coefficients ($\alpha_a$), are the age-specific rates in the reference cohort (1950); those of the cohort ($\beta_c$), are the rate ratio with respect to the reference cohort; and those of the period ($\gamma_p$), the ratio of rates relative to a prediction of an age-cohort model (residual). The results of the age, period and cohort effects are presented graphically with a confidence level of 95%.

The analyses were performed with the statistical program R. For the estimation of the age-period-cohort models, the Epi package was used and the Akaike information criterion (AIC) was used to compare the fit of the models.

**Results**

During the study period, there were 42,567 deaths from cervical cancer, among these, only 56 (0.13%) did not have age information, so they were excluded from the analysis. The age-adjusted mortality rate from cervical cancer for the period 1985-1989 was 12.26 deaths per 100,000 women-year, while for the period 2010-2014 it was 10.34 deaths per 100,000 women-year (Table 1), showing an APPC, controlled by age, of -1.38% (95% CI: -1.49% to -1.04%).

Estimates of mortality from cervical cancer presented a particular trend, with respect to age, an exponential trend was observed in the mortality rate up to 50 years, with a significant decrease in the slope up to 70 years, when it increases again. With respect to the cohort, in general, there is a decrease in risk for the younger cohorts, although an increasing trend was observed since the 60s, remaining below or at most at the same level as the 1950 cohort. For the period, an increase in the estimated risk is observed in the 90's, it remains constant until 2002 and then decreases (Figure 1).
Age, period and cohort effects on mortality from cervical cancer in Colombia between 1985 and 2014.

The results of the APC models are shown in Table 2. The model that best fits cervical cancer mortality includes effects of age, period and cohort, since it is the model with the lowest AIC (137.66). Additionally, by comparing models, the significance of these effects can be observed (4 vs 2, p-value= 0.000 and 5 vs 3, p-value= 0.000). On the other hand, a good fit of the model was obtained, since it explained 99.4% of the mortality variability (pseudo R\(^2\)= 99.4%).

### Discussion

The burden of cervical cancer is greatest in low- and middle-income countries, which account for approximately 90% of women who die of cervical cancer globally \(^{19}\). In Latin America, both incidence and mortality rates are higher than those of more developed countries such as the United States. At the regional level, it has been found that, in general, the highest rates of morbidity and mortality from cervical cancer are found in countries with the lowest human development index \(^{20}\).

During the period of this study, Colombia was located at an intermediate point between the countries of the region, in addition, a decrease in mortality over time (EAPC = -3.2) has been evidenced in different studies, which is consistent with the results found \(^{2,7,21}\). On the other hand, it is known that factors related to one's own sexual behavior and that of the partner increase the risk of HPV infection, a necessary cause for cervical cancer. Likewise, cofactors such as: high parity, smoking, prolonged use of oral contraceptives and sexually transmitted co-infections such as HIV, are associated with the appearance of this type of carcinoma \(^{22}\) and could explain, in part, the behavior of mortality.

The results show that cervical cancer mortality in Colombia is determined by age, period and cohort effects. Estimates of age-specific mortality rates are consistent with incidence estimates based on reports from population-based cancer registries, in which there is a fast-growing
trend up to age 45 years, followed by a gentler slope up to age 70 years when a steeper slope is observed again. This increase, observed after 70 years, may be related to the increase in life expectancy at birth in women, which has gone from 70 years in 1980 to 78 in 2010 and is consistent with the finding in Colombian women of a second peak prevalence of HPV infection in women over 55 years of age (13.2%), found in a study that analyzed a cohort of women in Bogotá D.C., which also suggests that the possible causes of this increase may be related to reactivation latent infections, hormonal changes, changes in partners or sexual behavior of their partners.

Regarding the effects of the periods, the decrease in the estimated mortality rates, starting in 2005, may be related to factors such as: the implementation of multiple strategies to favor the early detection of lesions, changes in the frequency of factors of risk and advances in the treatment of the disease, which could have had an effect mainly in the groups of younger women, as we will explain below. In the 1960s Profamilia and the Liga Colombiana contra el Cáncer (Colombian League Against Cancer) made the first attempts to establish a screening program, however, due to lack of organization and little participation, they were not successful, until in the 1990s a national program coordinated by the Instituto Nacional de Cancerología (National Cancer Institute), promoting the performance of cervicovaginal cytology outside the maternal care program, to reach the high-risk population. This program was regulated in 2000 by Resolution 412, which led to a decrease in the incidence of cervical cancer and therefore in mortality due to this; similarly, in 2004, colposcopy with biopsy was included for women affiliated with the subsidized regimen. Likewise, what has been observed since 2005 may be related to the decrease in the prevalence of some risk factors such as smoking, which went from 21.4% in 1993 to 12.8% in 2007. Another factor may be related to the fact that at the end of the 1990s a concomitant chemo-radiotherapy scheme with cisplatin began to be implemented for patients with locally advanced cancer, which showed an improvement in progression-free survival and a decrease in mortality.

The model estimated that the risk of death decreases until the cohorts born after the 60s, where it begins to rise until the younger cohorts, without reaching the levels of the 1950 cohort. Some possible explanations may be related to changes in the frequency of some cofactors, as well as risk factors for HPV infection. One of these cofactors is the long use of oral contraceptives, which began to be used in the 1960s, when the first contraceptive pill was approved in the United States and the first pills arrived in Colombia. From this moment, the cohorts began to be exposed to the use of oral contraceptives, likewise, this leads to modifying the sexual behavior of women, possibly increasing risk factors for HPV infection, such as the age of onset relationships and the number of sexual partners, increasing the risk of developing cervical cancer. This could be combined with poor access to the health system and therefore early detection of precancerous lesions, particularly in regions strongly affected by violence in some remote territories, especially during the 80s and 90s (decades in which women born between the 60s and 70s would begin to have an active sexual life), where illegal groups disputed control, which not only hindered access to health services but also made women the main victims of sexual abuse. This is also reflected in the cancer mortality atlases in Colombia, which have shown higher mortality in regions near navigable rivers, as well as in the Orinoquía.
In the future, an analysis using APC models will allow evaluating the effects of the incorporation of the human papillomavirus vaccine within the Expanded Program on Immunization (EPI) in Colombia, which included the HPV vaccine since August 2012, for through the implementation of the catch-up program for schoolgirls aged 9 to 17 \(^3\). Given that some studies have reported that vaccination with the bivalent or tetravalent vaccine can prevent up to 68% of cervical cancer and between 48-81% of other types of cancer related to HPV, a significant decrease in the cervical cancer mortality is expected in the corresponding cohorts. Likewise, when the 9-valent vaccine begins to be applied in the country, it is expected to prevent 88% of cervical cancer and 85-100% of other HPV-related cancers \(^1\), which could also be analyzed and evidenced in the future through these models.

On the other hand, Resolution 3280 of 2018 adopted the guidelines on the screening strategy for cervical cancer in the country, indicating cytology for women between 25 and 30 years of age, HPV testing between 30 and 69 years of age and VIA/VILI strategy for remote populations with low access to health systems \(^33\). The implementation of this program is expected to reduce the number of routine screening visits and create an adequate follow-up line to guarantee treatment within 30 days after diagnostic confirmation by colposcopy/biopsy \(^24\). The results of this regulation can be evaluated in the future and will most likely be reflected in period or cohort effects.

**Limitations**

Mortality data come from official death registries, which may be underreported, especially for periods prior to 1997, because the information collection system was done through the municipal mayors, which reported based on individual death certificates. No adjustment was made for registration coverage, which could lead to underreporting of mortality rates. Likewise, given that the denominators of the rates were taken from the population projections made by DANE, it is possible that they do not completely reflect the real population behavior; however, it is hoped that these differences have not been more accentuated in some age group or at some point in time \(^34\).

In addition, only information related to deaths coded with cause of death C53 was included, i.e., no redistribution of cases of malignant tumor of the uterus in unspecified part (C55) was made. The above could modify the observed changes in mortality by period, considering that the percentage of deaths reported as C55, of the total of those related to cancer of the uterus, has been decreasing over time (Table 1), especially in the first five years analyzed. However, this would not change the downward trend in mortality estimated since 2000 (Figure 1).

Another important consideration when analyzing the results is that the confidence intervals for the younger cohorts are quite wide, due to the few cases that are presented for these cohorts, so it is advisable that further analyses such as this one continue to be carried out to corroborate the trends obtained. Similarly, it should be kept in mind that the APPCs should be interpreted with care, since they are averages and therefore tend to be unstable when the study period is long.

Other studies are needed to directly link the possible causes of cervical cancer mortality trends in order to evaluate programs and new technologies ranging from screening to treatment.

**Conclusion**

Integrated cancer prevention campaigns, effective screening programs and effective access to treatment have played an important role in the reduction of cervical cancer mortality. Demographic factors and the demographic transition may be explanatory processes for the behavior of cancer mortality in the Colombian population, as well as the implementation of public policies within the health system in the last two decades.
References

1. International Agency for Research on Cancer. New Global Cancer Data: Globocan. IARC; 2020. Cited 2022. Available from: https://gco.iarc.fr/today.

2. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Over Time. IARC; 2020. Cited 2022. Available from: https://gco.iarc.fr/overtime/en.

3. Ahmedin J, Bray F, Center M, Ferlay J, Ward E. Global cancer statistics. Cancer J Clinicians. 2011; 61(2): 69-90. doi: 10.3322/caac.20107.

4. Pan American Health Organization (PAHO). Cancer in the Americas: Country Profiles.; 2013. Cited 2020. Available from: https://www.paho.org/hq/dmdocuments/2014/COLOMBIA-CANCER-PROFILE-2013.pdf.

5. Bosetti C, Malvezzi M, Chatenoud L, Levi F, La Vecchia C. Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol. 2005; 16(3): 489-511. doi: 10.1093/annonc/mdi086.

6. Pardo C, de Vries E, Buitrago L, Gamboa O. Atlas de mortalidad por cáncer en Colombia Bogotá: Ministerio de Protección Social. Instituto Nacional de Cancerología.; 2017.

7. Piñeros M, Gamboa O, Hernández-Suárez G, Pardo C, Bray F. Patterns and trends in cancer mortality in Colombia 1984-2008. Cancer Epidemiol. 2013; 37(3): 233-239. doi: 10.1016/j.canep.2013.02.003.

8. Piñeros M, Hernández G, Bray F. Increasing mortality rates of common malignancies in Colombia. Cancer. 2004; 101(10): 2285-2292. doi: 10.1002/cncr.20607.

9. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global Cancer Statistics. Cancer J Clinicians. 2004; 61(1): 69-90. doi: 10.3322/caac.20107.

10. Carstensen B. Age-period-cohort models for the Lexis diagram. Statistics Med. 2007; 26(15): 3018-3045. doi: 10.1002/sim.2764.

11. Holford T. Understanding the effects of age, period, and cohort on incidence and mortality rates. Ann Rev Publ Health. 1991; 12(1): 425-457. doi: 10.1146/annurev.pu.12.050191.002233

12. Goss P, Lee B, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarrí-Guerra Y, StLouis J, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013; 14(5): 391-436. doi: 10.1016/s1470-2045(13)70048-2.

13. Bray F, Jemal A, Gray N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012; 13(8): 790-801. doi: 10.1016/s1470-2045(12)70211-5.

14. Parkin D. The global health burden of infection-associated cancer in the year 2002. Internat J Cancer. 2006; 118(12): 3030-3044. doi: 10.1002/ijc.21731.

15. Mathew A, George P. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix—worldwide. Asian Pac J Cancer Prev. 2009; 10(4): 645-650.

16. Departamento Administrativo Nacional de Estadística DANE. Demografía y población; 2005. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion.

17. World Health Organization. Classifications. International Classification of Diseases (ICD); 1998. Cited: 2014 06 29. Available from: http://www.who.int/classifications/icd/en/.

18. National Cancer Institute. Surveillance, epidemiology, and end results program; 2018. Cited: 2018 01 22. Available from: https://seer.cancer.gov/stdpopulations/stdpop.19ages.html.
Age, period and cohort effects on mortality from cervical cancer in Colombia between 1985 and 2014.

19. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-2917. doi: 10.1002/ijc.25516.

20. Sierra MS, Soerjomataram I, Antoni S, Laversanne M, Piñeros M, de Vries E, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016; 44(1): S23-S42. doi: 10.1016/j.canep.2016.07.013.

21. Murillo R, Herrero R, Sierra M, Forman D. Cervical cancer in Central and South America: Burden of disease and status of disease control. Cancer Epidemiol. 2016; 44(1): S121-S130. doi: 10.1016/j.canep.2016.07.015.

22. Almonte M, Ginesa A, Molano M, Carcamo C, García PJ, Pérez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine. 2008; 26(Suppl 11): L16-L36. doi: 10.1016/j.vaccine.2008.06.008.

23. Molano M, Posso H, Méndez F, Murillo R, Van den Brule A, Ronderos M, et al. Historia natural de la infección por el virus del papiloma humano en una cohorte de Bogotá. Rev Colomb Cancerol. 2005; 9(4): 209-226.

24. Vorsters A, Bosch F, Bonanni P, Franco E, Baay M, Simas C, et al. Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report. BMC Proceedings. 2020; 14(8): 1-13. doi: 10.1186/s12919-020-00192-2.

25. Garcés-Palacio I, Altarac M, Kirby R, McClure L, Mulvihill B, Scarinci I. Contribution of health care coverage in cervical cancer screening follow-up: findings from a cross-sectional study in Colombia. Int J Gynecol Cancer. 2010; 10(7): 232-1239. 10.1111/IGC.0b013e3181e8dfb8.

26. Ministerio de la Protección Social. Acuerdo número 282 por el cual se fija el valor de la Unidad de Pago por Capitación del Plan Obligatorio de Salud de los Regímenes Contributivo y Subsidiado para el año 2005 y se dictan otras disposiciones. Bogotá: Ministerio de la Protección Social; 2004.

27. Ministerio de Salud y Protección Social. Socialización del informe final de evaluación de necesidades para la ampliación del Convenio Marco del Control del Tabaco. Cifras oficiales para Colombia; 2016. Cited 2022 agosto. Available from: https://www.minsalud.gov.co/Documents/General/Cifras-tabaco-Colombia.pdf.

28. Rose PG, Bundy BN, Watkins EB, Deppe G, Maiman MA, Clarke-Pearson DL, et al. Concurrent cisplatin-based radiotherapy, and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15): 1144-53. doi: 10.1056/NEJM199904153401502.

29. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019; 393(10167): 169-182. doi: 10.1016/S0140-6736(18)32470-X.

30. Galán CG. 50 años de la píldora anticonceptiva. Rev Chilena Obstet Ginecol. 2010; 75(4): 217-182. doi: 10.21149/spm.v58i6.7880.